Stock Scorecard



Stock Summary for Mustang Bio Inc (MBIO) - $0.22 as of 11/19/2024 6:15:47 AM EST

Total Score

8 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MBIO

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MBIO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MBIO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MBIO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MBIO (17 out of 90)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0

Latest News for for MBIO

Gene Therapy for SCID Market is Expected to Reach at a US$ 2.0 Billion by 2034 | Fact.MR Report 11/13/2024 12:30:00 PM
Mustang Bio Receives Positive Listing Determination from Nasdaq 11/12/2024 1:30:00 PM
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 ( HSV-1 oncolytic virus ) to Treat Malignant Glioma - Fortress Biotech ( NASDAQ:FBIO ) , Mustang Bio ( NASDAQ:MBIO ) 11/7/2024 1:30:00 PM
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 ( HSV-1 oncolytic virus ) to Treat Malignant Glioma 11/7/2024 1:30:00 PM
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds - Fortress Biotech ( NASDAQ:FBIO ) , Mustang Bio ( NASDAQ:MBIO ) 10/24/2024 6:10:00 PM
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds 10/24/2024 6:10:00 PM
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Stride ( NYSE:LRN ) 10/23/2024 10:36:00 AM
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - Establishment Labs Hldgs ( NASDAQ:ESTA ) 9/27/2024 10:46:00 AM
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights 8/13/2024 8:05:00 PM
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Fortress Biotech ( NASDAQ:FBIO ) , Mustang Bio ( NASDAQ:MBIO ) 6/21/2024 8:01:00 PM

Financial Details for MBIO

Company Overview

Ticker MBIO
Company Name Mustang Bio Inc
Country USA
Description Mustang Bio, Inc., a clinical-stage biopharmaceutical company, is focused on translating medical advances in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Worcester, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 0.22
Price 4 Years Ago 56.77
Last Day Price Updated 11/19/2024 6:15:47 AM EST
Last Day Volume 399,240
Average Daily Volume 3,317,771
52-Week High 1.68
52-Week Low 0.13
Last Price to 52 Week Low 69.23%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -16.89
Free Cash Flow Ratio 2.75
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 0.40
Total Cash Per Share 0.08
Book Value Per Share Most Recent Quarter -0.94
Price to Book Ratio 31.75
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 46,934,900
Market Capitalization 10,325,678
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 33.44%
Reported EPS 12 Trailing Months -1.33
Reported EPS Past Year -0.86
Reported EPS Prior Year -6.32
Net Income Twelve Trailing Months -23,416,000
Net Income Past Year -51,602,000
Net Income Prior Year -77,525,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 3,525,000
Total Cash Past Year 6,234,000
Total Cash Prior Year 75,656,000
Net Cash Position Most Recent Quarter 3,525,000
Net Cash Position Past Year -21,202,000
Long Term Debt Past Year 27,436,000
Long Term Debt Prior Year 27,436,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year 123,000
Total Stockholder Equity Prior Year 46,273,000
Total Stockholder Equity Most Recent Quarter -8,656,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -16,697,000
Free Cash Flow Per Share Twelve Trailing Months -0.36
Free Cash Flow Past Year -49,591,000
Free Cash Flow Prior Year -68,145,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.01
MACD Signal 0.00
20-Day Bollinger Lower Band 0.17
20-Day Bollinger Middle Band 0.28
20-Day Bollinger Upper Band 0.40
Beta 1.92
RSI 39.40
50-Day SMA 5.53
150-Day SMA 0.00
200-Day SMA 15.45

System

Modified 11/19/2024 6:16:33 AM EST